← 返回

EGFR 联合 TIL(肿瘤浸润淋巴细胞)在口腔鳞状细胞癌中的预后作用

英文原题:Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma.

查看英文原题

Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma.

PubMed 2022/07/25(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这些结果表明 CD3+肿瘤浸润 T 细胞的表达可以增强 EGFR 表达的预后价值,并值得作为 OSCC 的预后生物标志物进一步研究。

研究思路结论见上方概要

表皮生长因子受体(EGFR)作为头颈部肿瘤的通用预后生物标志物已广为人知,然而EGFR在口腔鳞状细胞癌(OSCC)中的具体预后价值仍存在争议。近年来,肿瘤浸润性T细胞的存在已被认为与多种疾病部位显著的生存优势相关。本研究将确定纳入T细胞特异性标志物(CD3、CD4和CD8)是否能增强EGFR在OSCC中的预后价值。

采用免疫组化染色对包含146例OSCC病例的组织芯片进行EGFR、CD3、CD4和CD8表达分析。EGFR和T细胞表达评分与临床病理参数及生存结局进行相关性分析。

结果显示,EGFR表达对总生存期(OS)无影响,但与EGFR阴性(EGFR-)患者相比,EGFR阳性(EGFR+)OSCC患者的无进展生存期(PFS)显著更差。CD3、CD4和CD8阳性肿瘤患者分别相比CD3、CD4和CD8阴性患者,OS显著更好,但对PFS无影响。EGFR+/CD3+联合表达与无淋巴结受累病例相关,且相比EGFR+/CD3-表达,OS显著更有利。在EGFR-患者中,CD3表达对OS或PFS无影响。EGFR/CD8和EGFR/CD4联合表达在各表达组之间对OS或PFS未显示显著差异。

展开英文摘要原文

Epidermal growth factor receptor (EGFR) is well known as a general prognostic biomarker for head and neck tumors, however the specific prognostic value of EGFR in oral squamous cell carcinoma (OSCC) is controversial. Recently, the presence of tumor-infiltrating T cells has been associated with significant survival advantages in a variety of disease sites. The present study will determine if the inclusion of T cell specific markers (CD3, CD4 and CD8) would enhance the prognostic value of EGFR in OSCCs.

Tissue microarrays containing 146 OSCC cases were analyzed for EGFR, CD3, CD4 and CD8 expression using immunohistochemical staining. EGFR and T cell expression scores were correlated with clinicopathological parameters and survival outcomes.

Results showed that EGFR expression had no impact on overall survival (OS), but EGFR-positive (EGFR+) OSCC patients demonstrated significantly worse progression free survival (PFS) compared to EGFR-negative (EGFR-) patients. Patients with CD3, CD4 and CD8-positive tumors had significantly better OS compared to CD3, CD4 and CD8-negative patients respectively, but no impact on PFS. Combined EGFR+/CD3+ expression was associated with cases with no nodal involvement and significantly more favorable OS compared to EGFR+/CD3- expression. CD3 expression had no impact on OS or PFS in EGFR- patients. Combinations of EGFR/CD8 and EGFR/CD4 expression showed no significant differences in OS or PFS among the expression groups.

Altogether these results suggest that the expression of CD3+ tumor-infiltrating T cells can enhance the prognostic value of EGFR expression and warrants further investigation as prognostic biomarkers for OSCC.

论文信息

作者
Wongpattaraworakul W、Gibson-Corley KN、Choi A、Buchakjian MR、Lanzel EA、Rajan Kd A、Simons AL
单位
Department of Oral Pathology, Radiology, and Medicine, College of Dentistry, University of Iowa, Iowa City, IA, United States.United States
期刊
Frontiers in oncology2022
原文标识
PubMed 35957892 · DOI 10.3389/fonc.2022.885236